Categories
- Aesthetic Medicine
- Aesthetic Surgery
- Ai
- ALS Treatment
- Anatomy
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Batten Disease Treatment
- BioEngineering
- BioInformatics
- Biology
- Biotechnology
- Bitcoin
- Brain Injury Treatment
- Cardiac Nursing
- Cardiac Regeneration
- Cardiac Remodeling
- Cardiac Rhythm Abnormalities
- Cardiac Surgery
- Cardiology
- Cardiomyopathies
- Cardiovascular Pharmacology
- Cell Medicine
- Cell Therapy
- Cerebral Palsy
- Cerebral Palsy Treatment
- Cheap Pharmacy
- Chemistry
- Clinical Cardiology
- Coronary Heart Diseases
- Cryptocurrency
- DNA
- Drug Dependency
- Drug Side Effects
- Drugs
- Eczema
- Elon Musk
- Embryology
- Erectile Dysfunction
- FDA Stem Cell Trials
- Femtomedicine
- Future Medicine
- Gene Medicine
- Gene Therapy
- Gene Therapy Trials
- Genetic Engineering
- Genetic Therapy
- Genetics
- Germ Line Engineering
- Heart Diseases
- HGH
- Hgh Injections
- Hormone Replacement Therapy
- Human Genetics
- Human Growth Hormone
- Human Immortality
- Hyperbaric Medicine
- Hypertension
- Hypothalamus
- Impotency
- Internet Pharmacy
- Interventional Cardiology
- IVF Treatment
- Lyme Disease
- Male Sexual Dysfunction
- Mars Colony
- Medical Business
- Medical School
- Medical Technology
- Medicine
- Mental Health
- Mesenchymal Stem Cells
- Micropenia
- Molecular Cardiology
- MS Treatment
- Muscular Dystrophy Treatment
- Myocardial Infarction
- Nanotechnology
- Online Pharmacy
- Oral Health
- Parkinson's Treatment
- Pediatric Cardiology
- Penis Enlargement
- Pet Stem Cell Therapy
- Pharmacy
- Picomedicine
- Premature Ejaculation
- Prescriptions
- Retinitis Pigmentosa
- Sermorelin
- Singularity
- Sleep
- Spacex
- Spinal Cord Injury Treatment
- Stem Cell Clinical Trials
- Stem Cell Experiments
- Stem Cell Human Trials
- Stem Cell Injections
- Stem Cell Research
- Stem Cell Transplant
- Stem Cell Treatments
- Testosterone
- Ulcerative Colitis
- Uncategorized
- Vascular Biology
- Ventricular Remodeling
- Wholesale Pharmacy
Archives
Category Archives: Stem Cell Research
FDA Approves Stemedica IND Application for Stemedyne(TM)-MSC In Cutaneous Photoaging
Posted: Published on September 28th, 2012
SAN DIEGO, Calif., Sept. 28, 2012 (GLOBE NEWSWIRE) -- via PRWEB - Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that the U.S. Food and Drug Administration (FDA) approved its application for an Investigational New Drug (IND) to assess the safety, tolerability and clinical effects of Stemedyne-MSC (Stemedica's human bone marrow-derived ischemia tolerant mesenchymal cells) in subjects with cutaneous photoaging resulting from overexposure to ultraviolet radiation. Curt M. Littler, M.D., F.A.A.D., dermatologist at Sharp Rees-Stealy Medical Group, Inc., is the principal investigator of the study. Dr. Littler commented, "This study is an important step forward in the field of dermatology. Photoaging is a universal condition. Damage from the sun's rays alters the skin's underlying structures, such as collagen, elastin, and blood vessels, and contributes to the creation of abnormal epidermal cells, which can become precancerous. By administering stem cells systemically, this study has the potential to target skin damage throughout the body and promises to pave the way for new treatment approaches for photoaged skin." The IND approval allows Stemedica to initiate a clinical trial at medical centers within the United States. The clinical trial will be a Phase I/IIa multi-center … Continue reading
Posted in Stem Cell Research
Comments Off on FDA Approves Stemedica IND Application for Stemedyne(TM)-MSC In Cutaneous Photoaging
International Stem Cell Corp to Participate in Upcoming Investor Conference
Posted: Published on September 28th, 2012
CARLSBAD, CA--(Marketwire - Sep 27, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, today announced that Executive Vice President, Dr. Simon Craw will attend and present at the SeeThru Equity Fall Smallcap and Microcap Conference on October 2, 2012 at the Cornell Club in midtown Manhattan, NY. SeeThru Equity Fall Smallcap and Microcap Conference Date: Tuesday, October 2, 2012 Time: 8:30 am EDT Location: The Cornell Club in midtown Manhattan, NY Please contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell's management team. You may also contact Mark McPartland with MZ Group via email markmcp@mzgroup.us or phone 1-212-301-7130 to arrange a meeting with management. You may register for the conference by clicking SeeThruEquity Fall Conference Attendee Registration or visting the SeeThru Equity website http://www.seethruequity.com Additional information of the investor presentation will be available on the investor relations section of the Company's website http://www.internationalstemcell.com. A video replay webcast will be available for viewing approximately 24hours after the company presentation. About International Stem Cell Corporation International Stem … Continue reading
Posted in Stem Cell Research
Comments Off on International Stem Cell Corp to Participate in Upcoming Investor Conference
Three-dimensional fiber scaffold promotes large-scale stem cell proliferation and differentiation
Posted: Published on September 27th, 2012
Pluripotent embryonic stem cells encapsulated in the fiber scaffold developed at IBN. Credit: A*STAR Institute of Bioengineering and Nanotechnology Thanks to the ability of pluripotent stem cells to self-renew and differentiate into a wide variety of specialized cell types, they are expected to revolutionize the treatment of illnesses such as type I diabetes and Parkinson's disease. Before this becomes a reality, however, scientists must develop culture systems to mass-produce these cells. To overcome the limitations of previous single-layer-substrate systems, a research team in Singapore has developed three-dimensional scaffolds that stimulate stem cell proliferation and differentiation under defined chemical conditions. Importantly, the system can be scaled up. The scaffolds consist of microscopic fibers obtained by weaving together polymer strands bearing opposite charges. Hongfang Lu and Andrew Wan from the A*STAR Institute of Bioengineering and Nanotechnology led the research. Wan notes that the fiber-based scaffold not only avoids the need to consume large quantities of key growth factors, but it would also shield the cells from the shear stresses generated in large-scale bioreactors. To manufacture the scaffold, the researchers opted for a positively charged biopolymer called chitin, which they extracted from crab shell, and a negatively charged polymer called sodium alginate. After … Continue reading
Posted in Stem Cell Research
Comments Off on Three-dimensional fiber scaffold promotes large-scale stem cell proliferation and differentiation
Moffitt Cancer Center researchers find possible key to regulation of ovarian cancer stem cells
Posted: Published on September 27th, 2012
Public release date: 27-Sep-2012 [ | E-mail | Share ] Contact: Kim Polacek kim.polacek@moffitt.org 813-745-7408 H. Lee Moffitt Cancer Center & Research Institute Researchers at Moffitt Cancer Center have discovered that the micro ribonucleic acid miR-214 plays a critical role in regulating ovarian cancer stem cell properties. This knowledge, said the researchers, could pave the way for a therapeutic target for ovarian cancer. The study appears in a recent issue of the The Journal of Biological Chemistry. According to the study's lead author, Jin Q. Cheng, Ph.D., M.D., senior member of the Molecular Oncology Department and Molecular Oncology and Drug Discovery Program at Moffitt, certain miRNAs can cause therapeutic resistance and cancer metastasis by regulating multiple gene targets. Previous work has shown that one microRNA miR-214 is elevated in cancer. In ovarian cancer, up-regulated miR-214 has been associated with late-stage and high-grade tumors. In past research, miR-214 has also been associated with resistance to the chemotherapy drug cisplatin, but the role played by miR-214 in cancer stem cells had not been determined. "Evidence suggests that cancer stem cells are responsible for cancer initiation, progression, metastasis, chemoresistance and relapse," Cheng said. "Data are emerging to support the role of both miRNAs … Continue reading
Posted in Stem Cell Research
Comments Off on Moffitt Cancer Center researchers find possible key to regulation of ovarian cancer stem cells
Kinase Inhibitors Quicken Stem Cell Production Process
Posted: Published on September 27th, 2012
September 26, 2012 Connie K. Ho for redOrbit.com Your Universe Online Scientists from the La Jolla, California-based Sanford-Burnham Medical Research Institute recently discovered kinase inhibitors, which could help facilitate the production of stem cells in the laboratory as well as increase the amount of cells for projects related to disease research and drug development. Researchers were initially interested in quickening the process utilized in the production of induced pluripotent stem cells (iPSCs), a special group of stem cells that can be derived from any kind of an adult cell in the laboratory. iPSCs have been used to produce cells of all types, including cells from the brain, heart and muscles. The team of investigators found that kinase inhibitors could limit the activity of kinase, enzymes that assist in cellular communication, growth and survival. When they combined starter cells along with kinase inhibitors, they discovered that they could produce more iPSCs than the method that has been used in the past by scientists. Generating iPSCs depends on the regulation of communication networks within cells, remarked the studys senior author Tariq Rana, program director in Sanford-Burnhams Childrens Health Research Center, in a prepared statement. So, when you start manipulating which genes are … Continue reading
Posted in Stem Cell Research
Comments Off on Kinase Inhibitors Quicken Stem Cell Production Process
Celprogen Obtained US Patent (US8,236,297B2) Method of Treating Lactose Intolerance Utilizing Genetically Engineered …
Posted: Published on September 27th, 2012
LOS ANGELES--(BUSINESS WIRE)-- Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they obtained a Patent for Treating Lactose Intolerance Utilizing Genetically Engineered Bacteria US8,236,297B2. Acquired lactase deficiency is the most common disorder of complex carbohydrate absorption throughout the world, affecting 75% of world population. In the United States 15% of Caucasians, over 50% of Hispanics and over 80% of African-Americans suffer from lactose intolerance. The present invention relates to genetically engineered bacteria that are able to colonize the mammalian intestine and actively produce mammalian lactase. This lactose-digesting enzyme is stable and active under the conditions normally found in the mammalian small intestine. Experimental subjects colonized with the genetically engineered bacteria show improved ability to digest lactose in dairy foods. About Celprogen Inc. Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing a proprietary portfolio of unique therapeutics products and life science research tools that includes genetic engineering technologies, stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in San Pedro, California, Celprogen is committed to the research, development, and manufacture … Continue reading
Posted in Stem Cell Research
Comments Off on Celprogen Obtained US Patent (US8,236,297B2) Method of Treating Lactose Intolerance Utilizing Genetically Engineered …
Seven days: 21–27 September 2012
Posted: Published on September 26th, 2012
Business | Events | Policy | People | Research | Trend watch Database case The American Chemical Society (ACS), the worlds largest scientific society, is likely to have to pay US$11.5million in compensation to a small start-up company after a ruling by the Ohio Supreme Court on 18September. The court ruled that the ACS, based in Washington DC, filed a lawsuit to unfairly suppress chemical-informatics firm Leadscope of Columbus, Ohio. See page482 for more. Drug-makers unite Ten giant pharmaceutical companies have formed a non-profit organization called TransCelerate BioPharma, with the goal of making clinical trials more efficient. By setting universal standards in trial design and data collection, the group could shave time and expense off the drug-development process, says Garry Neil, head of TransCelerate and a former vice-president of science and technology at Johnson & Johnson. Smaller companies are invited to join the team. See go.nature.com/jj2sky for more. Dark Energy Survey Collaboration/FERMILAB First light for dark-energy lens A camera designed to hunt for signs of dark energy, a force thought to be responsible for the Universes rapid expansion, snapped its first images on 12September. The images from the Dark Energy Survey camera (Nature 489, 190191; 2012), which is mounted on … Continue reading
Posted in Stem Cell Research
Comments Off on Seven days: 21–27 September 2012
Pacemaker from Stem Cells Receives Research Funding
Posted: Published on September 26th, 2012
(SACRAMENTO, Calif.) - Deborah K. Lieu, a stem cell scientist in cardiovascular medicine at UC Davis Health System, has received a $1.3 million research grant from the California Institute for Regenerative Medicine (CIRM) to develop stem cells that could serve as a biological alternative to the electronic pacemakers that people now use to regulate heart rhythm. According to Lieu, each year 350,000 cardiology patients with abnormal heart rhythms receive electronic pacemakers to maintain a normal heart beat. The devices, while effective, have several disadvantages, including limited battery life and poor response to changing heart rates, such as when a person is exercising. Lieu, who is working with colleague Nipavan Chiamvimonvat, the Roger Tatarian Endowed Professor of Cardiovascular Medicine at UC Davis, plans to examine ways to improve the generation of pacemaking cells using human-induced pluripotent stem cells (hiPSCs), potentially creating what she calls a "biopacemaker." "There are more than 3 million patients around the country who are dependent on electronic pacemakers," said Lieu. "Each one costs about $58,000 to implant and requires follow-up surgery about every 5 to 10 years to change batteries. Creating a biopacemaker from stem cells would avoid the burden of battery replacement and provide the physiological … Continue reading
Posted in Stem Cell Research
Comments Off on Pacemaker from Stem Cells Receives Research Funding
Research and Markets: Cell Culture Life Science Dashboard Series 4 (China)
Posted: Published on September 26th, 2012
DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/j9wdgd/cell_culture_life) has announced the addition of the "Cell Culture Life Science Dashboard Series 4 (China)" report to their offering. The growth and propagation of mammalian cells in culture is a routine but critical precursor to the investigation of such fundamental cellular processes as gene expression and protein function and to the development of therapeutics. Cell culture products are widely used not only by scientists working with traditional cell lines but also by researchers engaged in experiments with such emerging model systems as stem cells and engineered cell lines. This Cell Culture Dashboard for the Chinese market was developed based upon the aggregated responses to a 21-question survey and completed by 398 scientists actively engaged in mammalian cell culture predominantly located in China. This Dashboard reveals key market indicators for the research market for cell culture products as a whole as well as for the following product segments: - Basal media - Fetal bovine serum - Animal sera - Balanced salt solutions - Serum free media - Dry powdered media More here: Research and Markets: Cell Culture Life Science Dashboard Series 4 (China) … Continue reading
Posted in Stem Cell Research
Comments Off on Research and Markets: Cell Culture Life Science Dashboard Series 4 (China)
Cancer Stem Cells Drug Pipeline Update 2012
Posted: Published on September 24th, 2012
NEW YORK, Sept. 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cancer Stem Cells Drug Pipeline Update 2012 http://www.reportlinker.com/p0980850/Cancer-Stem-Cells-Drug-Pipeline-Update-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today 203 companies plus partners developing 243 cancer stem cells and developmental pathways drugs in 684 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 123 drugs. Cancer Stem Cells Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 different targets. These targets are further categorized on in the software application by 38 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath. How May Drug Pipeline Update Be of Use? * Show investors/board/management that you are right … Continue reading
Posted in Stem Cell Research
Comments Off on Cancer Stem Cells Drug Pipeline Update 2012
We cordially invite you to collaborate with us (as Speaker/Exhibitor/Sponsor/Media Partner) for “10th Annual Conference on Stem Cell and Regenerative Medicine” scheduled on August 13-14, 2018 in London, UK.
For meeting details visit: https://stemcell-regenerativemedicine.conferenceseries.com/